GE Healthcare warned European providers Feb. 7 to discontinue the use of gadodiamide (Omniscan) for patients who may be at risk for a rare and life-threatening skin disease.
GE Healthcare warned European providers Feb. 7 to discontinue the use of gadodiamide (Omniscan) for patients who may be at risk for a rare and life-threatening skin disease.
Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, may occur in patients with moderate to end-stage kidney disease after an MRI or MR angiography study with gadolinium-based contrast media. NSF causes problems in the joints and in some cases quickly results in loss of mobility or death.
The manufacturer's warning is associated with a new ruling from the European Medicines Agency, the regulatory body for pharmaceuticals in the European Union. The EMEA decision was also released Feb. 7.
In line with the EMEA alert, GE advises that Omniscan is contraindicated in the following cases:
The manufacturer also advised caution when administering gadodiamide to neonates and infants up to one year old, again in line with EMEA guidance.
As of Feb.7, GE had received 96 reports of NSF following Omniscan administration. In most cases, high doses were administered. Although regulatory agencies have received reports of NSF following administration of other gadolinium-based MR agents, most have been linked to Omniscan, according to GE.
The company advised physicians to use general radiography and other alternative imaging techniques for patients with severely compromised renal function. Physicians can call the following numbers if they have questions or to report cases:
For more information from the Diagnostic Imaging archives:
European authorities warn against use of Omniscan in at-risk patients
FDA renews warning on gadolinium in patients with weak kidneys
Gadolinium-related problems stem from one specific agent
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 5th 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 5th 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 5th 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.